secwatch.observer — SEC 8-K summary
======================================

Issuer:     DMK PHARMACEUTICALS Corp (—)
CIK:        0000887247
Form:       8-K
Filed at:   2023-07-24T23:59:59+00:00
Accession:  0001387131-23-008595
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CFO David Benedicto resigns; President/COO Marguglio named interim CFO
----------------------------------------------------------------------

- David C. Benedicto resigned as CFO and principal accounting officer, effective July 21, 2023.
- Resignation not due to any disagreement with the company or auditors on financial matters.
- David J. Marguglio, President and COO, appointed interim CFO while a permanent replacement is sought.
- Marguglio has been with Adamis since 2009 and previously served as CEO until the DMK merger in May 2023.
- Company will commence a search for a new CFO; no formal arrangement or understanding with Mr. Marguglio.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/887247/000138713123008595/0001387131-23-008595-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/887247/000138713123008595/admp-8k_071823.htm
  HTML page:      https://secwatch.observer/filing/0001387131-23-008595

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer